VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 17, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM) (the "Company") announced today that it has granted to directors, officers, consultants, employees and management of the Company, to purchase a total of 1,550,000 common shares in the capital of the Company at a price of $0.10 per common share for a period of five years ending December 17, 2017. The options have been granted under and are governed by the terms of the Company's current stock option plan and are subject to vesting provisions.
Sirona Biochem Corp. also announces that finder's fees totaling $16,000 and 160,000 broker warrants were returned to Sirona Biochem by Raymond James Ltd. (RJL) as it was determined RJL was not sufficiently involved in the March 2012 non-brokered private placement transaction to warrant finder's fee compensation.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.